Treatment Response in Enteric Fever in an Era of Increasing Antimicrobial Resistance: An Individual Patient Data Analysis of 2092 Participants Enrolled into 4 Randomized, Controlled Trials in Nepal. (28th February 2017)

• Record Type: Journal Article
• Authors: Thompson, Corinne N.; Karkey, Abhilasha; Dongol, Sabina; Arjyal, Amit; Wolbers, Marcel; Darton, Thomas; Farrar, Jeremy J.; Thwaites, Guy E.; Dolecek, Christiane; Basnyat, Buddha; Baker, Stephen
• Is Part Of: Clinical infectious diseases. Volume 64:Number 11(2017)
• Page Start: 1522
• Page End: 1531
• Publication Date: 2017-02-28
• Subjects: antimicrobial resistance -- typhoid -- enteric fever -- Nepal -- fluoroquinolone.; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/cix185
• Languages: English
• ISSNs: 1058-4838

Abstract

Summary: This is the largest collection of enteric fever treatment data. The results, from trials conducted in Nepal since 2005, confirm that fluoroquinolones are failing for enteric fever treatment. The World Health Organization enteric fever treatment guidelines should be modified. Abstract: Background: Enteric fever, caused by Salmonella Typhi and Salmonella Paratyphi A, is the leading cause of bacterial febrile disease in South Asia. Methods: Individual data from 2092 patients with enteric fever randomized into 4 trials in Kathmandu, Nepal, were pooled. All trials compared gatifloxacin with 1 of the following comparator drugs: cefixime, chloramphenicol, ofloxacin, or ceftriaxone. Treatment outcomes were evaluated according to antimicrobial if S . Typhi/Paratyphi were isolated from blood. We additionally investigated the impact of changing bacterial antimicrobial susceptibility on outcome. Results: Overall, 855 (41%) patients had either S . Typhi (n = 581, 28%) or S . Paratyphi A (n = 274, 13%) cultured from blood. There were 139 (6.6%) treatment failures with 1 death. Except for the last trial with ceftriaxone, the fluoroquinolone gatifloxacin was associated with equivalent or better fever clearance times and lower treatment failure rates in comparison to all other antimicrobials. However, we additionally found that the minimum inhibitory concentrations (MICs) against fluoroquinolones have risen significantly since 2005 and were associated with increasing fever clearance times. Notably, all organisms were susceptible to ceftriaxone throughout the study period (2005–2014), and the MICs against azithromycin declined, confirming the utility of these alternative drugs for enteric fever treatment. Conclusion: The World Health Organization and local government health ministries in South Asia still recommend fluoroquinolones for enteric fever. This policy should change based on the evidence provided here. Rapid diagnostics are urgently required given the large numbers of suspected enteric fever patients with a negative culture.